A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia

Lung Cancer

Volumn 111, Issue , 2017, Pages 1-5

  Fujimoto, Daichi ^a   Morimoto, Takeshi ^a,b   Ito, Jiro ^a   Sato, Yuki ^a   Ito, Munehiro ^a   Teraoka, Shunsuke ^a   Otsuka, Kojiro ^a   Nagata, Kazuma ^a   Nakagawa, Atsushi ^a   Tomii, Keisuke ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Interstitial lung disease; Interstitial pneumonia; Nivolumab; Non small cell lung cancer

Indexed keywords

NIVOLUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG ADENOCARCINOMA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NON SMALL CELL LUNG CANCER; OPEN STUDY; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; VERY ELDERLY; VITAL CAPACITY; CANCER STAGING; COMPLICATION; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; RETREATMENT; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PILOT PROJECTS; RETREATMENT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85021146658     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.06.008     Document Type: Article

References (33)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics. CA: Cancer J. Clin. 66:1 (2016), 7–30.
2. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M.A., Lubiniecki, G.M., Shentu, Y., Rangwala, R., Brahmer, J.R., Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375:19 (2016), 1823–1833.
3. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., Barlesi, F., Kohlhaufl, M., Arrieta, O., Burgio, M.A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D.E., Gettinger, S.N., Rudin, C.M., Rizvi, N., Crino, L., Blumenschein, G.R. Jr., Antonia, S.J., Dorange, C., Harbison, C.T., Graf Finckenstein, F., Brahmer, J.R., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:17 (2015), 1627–1639.
4. Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Aren Frontera, O., Havel, L., Steins, M., Garassino, M.C., Aerts, J.G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C.T., Lestini, B., Spigel, D.R., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373:2 (2015), 123–135.
5. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M., Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:26 (2012), 2443–2454.
6. Travis, W.D., Costabel, U., Hansell, D.M., King, T.E. Jr., Lynch, D.A., Nicholson, A.G., Ryerson, C.J., Ryu, J.H., Selman, M., Wells, A.U., Behr, J., Bouros, D., Brown, K.K., Colby, T.V., Collard, H.R., Cordeiro, C.R., Cottin, V., Crestani, B., Drent, M., Dudden, R.F., Egan, J., Flaherty, K., Hogaboam, C., Inoue, Y., Johkoh, T., Kim, D.S., Kitaichi, M., Loyd, J., Martinez, F.J., Myers, J., Protzko, S., Raghu, G., Richeldi, L., Sverzellati, N., Swigris, J., Valeyre, D., An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188:6 (2013), 733–748.
7. Bouros, D., Hatzakis, K., Labrakis, H., Zeibecoglou, K., Association of malignancy with diseases causing interstitial pulmonary changes. Chest 121:4 (2002), 1278–1289.
8. Jin, G.Y., Lynch, D., Chawla, A., Garg, K., Tammemagi, M.C., Sahin, H., Misumi, S., Kwon, K.S., Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology 268:2 (2013), 563–571.
9. Sverzellati, N., Guerci, L., Randi, G., Calabro, E., La Vecchia, C., Marchiano, A., Pesci, A., Zompatori, M., Pastorino, U., Interstitial lung diseases in a lung cancer screening trial. Eur. Respir. J. 38:2 (2011), 392–400.
10. Raghu, G., Chen, S.Y., Yeh, W.S., Maroni, B., Li, Q., Lee, Y.C., Collard, H.R., Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir. Med. 2:7 (2014), 566–572.
11. Omori, T., Tajiri, M., Baba, T., Ogura, T., Iwasawa, T., Okudela, K., Takemura, T., Oba, M.S., Maehara, T., Nakayama, H., Tsuboi, M., Masuda, M., Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann. Thorac. Surg. 100:3 (2015), 954–960.
12. Fujimoto, D., Kato, R., Morimoto, T., Shimizu, R., Sato, Y., Kogo, M., Ito, J., Teraoka, S., Nagata, K., Nakagawa, A., Otsuka, K., Tomii, K., Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer. PLoS One, 11(12), 2016, e0168465.
13. Costabel, U., Inoue, Y., Richeldi, L., Collard, H.R., Tschoepe, I., Stowasser, S., Azuma, A., Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am. J. Respir. Crit. Care Med. 193:2 (2016), 178–185.
14. Kenmotsu, H., Naito, T., Kimura, M., Ono, A., Shukuya, T., Nakamura, Y., Tsuya, A., Kaira, K., Murakami, H., Takahashi, T., Endo, M., Yamamoto, N., The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J. Thorac. Oncol. 6:7 (2011), 1242–1246.
15. Enomoto, Y., Inui, N., Kato, T., Baba, T., Karayama, M., Nakamura, Y., Ogura, T., Suda, T., Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Lung Cancer 96 (2016), 63–67.
16. Iwata, T., Yoshino, I., Yoshida, S., Ikeda, N., Tsuboi, M., Asato, Y., Katakami, N., Sakamoto, K., Yamashita, Y., Okami, J., Mitsudomi, T., Yamashita, M., Yokouchi, H., Okubo, K., Okada, M., Takenoyama, M., Chida, M., Tomii, K., Matsuura, M., Azuma, A., Iwasawa, T., Kuwano, K., Sakai, S., Hiroshima, K., Fukuoka, J., Yoshimura, K., Tada, H., Nakagawa, K., Nakanishi, Y., A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: west Japan Oncology Group 6711 L (PEOPLE Study). Respir. Res., 17(1), 2016, 90.
17. Nishino, M., Cardarella, S., Dahlberg, S.E., Araki, T., Lydon, C., Jackman, D.M., Rabin, M.S., Hatabu, H., Johnson, B.E., Interstitial lung abnormalities in treatment-naive advanced non-small-cell lung cancer patients are associated with shorter survival. Eur. J. Radiol. 84:5 (2015), 998–1004.
18. Minegishi, Y., Kokuho, N., Miura, Y., Matsumoto, M., Miyanaga, A., Noro, R., Saito, Y., Seike, M., Kubota, K., Azuma, A., Kida, K., Gemma, A., Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema. Lung Cancer 85:2 (2014), 258–263.
19. Arai, T., Kagawa, T., Sasaki, Y., Sugawara, R., Sugimoto, C., Tachibana, K., Kitaichi, M., Akira, M., Hayashi, S., Inoue, Y., Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. Respirology 21:8 (2016), 1431–1437.
20. Ryerson, C.J., Vittinghoff, E., Ley, B., Lee, J.S., Mooney, J.J., Jones, K.D., Elicker, B.M., Wolters, P.J., Koth, L.L., King, T.E. Jr., Collard, H.R., Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 145:4 (2014), 723–728.
21. Sato, T., Teramukai, S., Kondo, H., Watanabe, A., Ebina, M., Kishi, K., Fujii, Y., Mitsudomi, T., Yoshimura, M., Maniwa, T., Suzuki, K., Kataoka, K., Sugiyama, Y., Kondo, T., Date, H., Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J. Thorac. Cardiovasc. Surg. 147:5 (2014), 1604–1611 e3.
22. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Muller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L., Schunemann, H.J., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183:6 (2011), 788–824.
23. Nishino, M., Ramaiya, N.H., Awad, M.M., Sholl, L.M., Maattala, J.A., Taibi, M., Hatabu, H., Ott, P.A., Armand, P.F., Hodi, F.S., PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin. Cancer Res. 22:24 (2016), 6051–6060.
24. Naidoo, J., Wang, X., Woo, K.M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J.E., Segal, N.H., Callahan, M.K., Lesokhin, A.M., Rosenberg, J., Voss, M., Rudin, C.M., Rizvi, H., Hou, X., Rodriguez, K., Albano, M., Gordon, R.A., Leduc, C., Rekhtman, N., Harris, B., Menzies, A.M., Guminski, A.D., Carlino, M.S., Kong, B.Y., Wolchok, J.D., Postow, M.A., Long, G.V., Hellmann, M.D., Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J. Clin. Oncol., 2016.
25. Watanabe, N., Niho, S., Kirita, K., Umemura, S., Matsumoto, S., Yoh, K., Ohmatsu, H., Goto, K., Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother. Pharmacol. 76:1 (2015), 69–74.
26. Kato, M., Shukuya, T., Takahashi, F., Mori, K., Suina, K., Asao, T., Kanemaru, R., Honma, Y., Muraki, K., Sugano, K., Shibayama, R., Koyama, R., Shimada, N., Takahashi, K., Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer, 14(508), 2014.
27. Masai, K., Tsuta, K., Motoi, N., Shiraishi, K., Furuta, K., Suzuki, S., Asakura, K., Nakagawa, K., Sakurai, H., Watanabe, S.I., Hiraoka, N., Asamura, H., Clinicopathological, immunohistochemical, and genetic features of primary lung adenocarcinoma occurring in the setting of usual interstitial pneumonia pattern. J. Thorac. Oncol. 11:12 (2016), 2141–2149.
28. Fujimoto, D., Tomii, K., Otoshi, T., Kawamura, T., Tamai, K., Takeshita, J., Tanaka, K., Matsumoto, T., Monden, K., Nagata, K., Otsuka, K., Nakagawa, A., Hata, A., Tachikawa, R., Hamakawa, H., Katakami, N., Takahashi, Y., Imai, Y., Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. Lung Cancer 80:2 (2013), 159–164.
29. Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Perez-Gracia, J.L., Han, J.Y., Molina, J., Kim, J.H., Arvis, C.D., Ahn, M.J., Majem, M., Fidler, M.J., de Castro, G. Jr., Garrido, M., Lubiniecki, G.M., Shentu, Y., Im, E., Dolled-Filhart, M., Garon, E.B., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:10027 (2016), 1540–1550.
30. Sacher, A.G., Gandhi, L., Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol. 2:9 (2016), 1217–1222.
31. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., Miller, M.L., Rekhtman, N., Moreira, A.L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E.B., Merghoub, T., Wolchok, J.D., Schumacher, T.N., Chan, T.A., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:6230 (2015), 124–128.
32. Demopoulos, K., Arvanitis, D.A., Vassilakis, D.A., Siafakas, N.M., Spandidos, D.A., MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J. Cell. Mol. Med. 6:2 (2002), 215–222.
33. Xiao, D., Pan, H., Li, F., Wu, K., Zhang, X., He, J., Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma. Oncotarget 7:16 (2016), 22857–22864.